Adamis Pharmaceuticals (NASDAQ:ADMP) was upgraded by equities research analysts at B. Riley from a “sell” rating to a “neutral” rating in a research note issued on Tuesday, BenzingaRatingsTable reports.

Several other research firms have also weighed in on ADMP. Raymond James reaffirmed a “buy” rating on shares of Canadian Natural Resources in a research report on Friday, May 10th. Dawson James started coverage on Adamis Pharmaceuticals in a research note on Tuesday, July 2nd. They issued a “buy” rating for the company. Finally, Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Tuesday, July 16th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Adamis Pharmaceuticals has an average rating of “Buy” and a consensus target price of $4.72.

Shares of NASDAQ ADMP traded down $0.05 during trading hours on Tuesday, hitting $1.11. The stock had a trading volume of 483,471 shares, compared to its average volume of 519,771. The firm has a market capitalization of $52.88 million, a P/E ratio of -1.11 and a beta of 1.36. The company’s 50-day moving average price is $1.32. Adamis Pharmaceuticals has a 52 week low of $1.14 and a 52 week high of $4.25. The company has a quick ratio of 1.24, a current ratio of 1.53 and a debt-to-equity ratio of 0.03.

Adamis Pharmaceuticals (NASDAQ:ADMP) last issued its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04). Adamis Pharmaceuticals had a negative net margin of 239.53% and a negative return on equity of 94.94%. The firm had revenue of $4.91 million during the quarter, compared to analyst estimates of $5.95 million. Equities research analysts anticipate that Adamis Pharmaceuticals will post -0.44 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Jane Street Group LLC bought a new position in shares of Adamis Pharmaceuticals in the fourth quarter worth $31,000. Wedbush Securities Inc. bought a new stake in Adamis Pharmaceuticals during the first quarter valued at $39,000. Virtu Financial LLC purchased a new stake in Adamis Pharmaceuticals during the first quarter valued at about $43,000. National Asset Management Inc. raised its position in Adamis Pharmaceuticals by 28.9% during the first quarter. National Asset Management Inc. now owns 29,920 shares of the specialty pharmaceutical company’s stock valued at $64,000 after purchasing an additional 6,710 shares in the last quarter. Finally, Barclays PLC purchased a new stake in Adamis Pharmaceuticals during the fourth quarter valued at about $110,000. 21.79% of the stock is owned by hedge funds and other institutional investors.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Featured Article: What is a good dividend yield?

Analyst Recommendations for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.